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A B S T R A C T
Cysteine and glycine rich protein 3 (CSRP3) encodes Muscle LIM Protein (MLP), a well-established disease gene for
Hypertrophic Cardiomyopathy (HCM). MLP, in contrast to the proteins encoded by the other recognised HCM
disease genes, is non-sarcomeric, and has important signalling functions in cardiomyocytes. To gain insight into
the disease mechanisms involved, we generated a knock-in mouse (KI) model, carrying the well documented
HCM-causing CSRP3 mutation C58G.
In vivo phenotyping of homozygous KI/KI mice revealed a robust cardiomyopathy phenotype with diastolic
and systolic left ventricular dysfunction, which was supported by increased heart weight measurements.
Transcriptome analysis by RNA-seq identiﬁed activation of pro-ﬁbrotic signalling, induction of the fetal gene
programme and activation of markers of hypertrophic signalling in these hearts. Further ex vivo analyses vali-
dated the activation of these pathways at transcript and protein level. Intriguingly, the abundance of MLP
decreased in KI/KI mice by 80% and in KI/+ mice by 50%. Protein depletion was also observed in cellular
studies for two further HCM-causing CSRP3 mutations (L44P and S54R/E55G). We show that MLP depletion is
caused by proteasome action. Moreover, MLP C58G interacts with Bag3 and results in a proteotoxic response in
the homozygous knock-in mice, as shown by induction of Bag3 and associated heat shock proteins.
In conclusion, the newly generated mouse model provides insights into the underlying disease mechanisms of
cardiomyopathy caused by mutations in the non-sarcomeric protein MLP. Furthermore, our cellular experiments
suggest that protein depletion and proteasomal overload also play a role in other HCM-causing CSPR3mutations
that we investigated, indicating that reduced levels of functional MLP may be a common mechanism for HCM-
causing CSPR3 mutations.
1. Introduction
Muscle LIM protein (MLP) is predominantly expressed in striated
muscle tissues [1]. It had originally been identiﬁed as a Z-disc protein
[2], but was also subsequently detected in the cytoplasm and the nu-
cleus [3, 4]. Importantly, we have shown that it is not an integral part
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of the cardiac sarcomere: MLP co-puriﬁes with cytosolic, but not with
sarcomeric proteins and can be extracted under mild conditions where
sarcomeric structures are preserved [4]. In agreement with its multiple
sub-cellular localisations, various binding partners have been identiﬁed
in the Z-disc, at the membranes and in the nucleus (reviewed in [5]).
MLP's function in the heart was initially suggested to be part of a Z-disc
based stretch sensor [2], but more recent work has reclassiﬁed MLP's
functions away from stretch sensing [4], to an alternative role of
modulating protein kinase C alpha (PKCα) activity in the myocardium
[6].
The crucial physiological role of MLP in cardiac integrity is high-
lighted by the fact that deletion of its encoding gene (cysteine and
glycine rich protein 3, Csrp3) causes dilated cardiomyopathy (DCM) in
mice [7]. Mutations in the human CSRP3 gene have subsequently been
associated with autosomal dominant DCM and hypertrophic cardio-
myopathy (HCM) [8–11]. A recent study has demonstrated an excess of
CSRP3 variants in HCM cases over control populations [12], providing
conﬁdence that CSRP3mutations do indeed contribute to HCM. For one
of these mutations, CSRP3 p.C58G, there is strikingly clear genetic
evidence of a causative role, supported by co-segregation with a HCM
phenotype in a large four-generation family and genome-wide linkage
analysis [4]. At the molecular level, the mutation is thought to abolish
the coordination of a zinc ion in the ﬁrst LIM domain, known to be
crucial for the stability of the domain. Hence, CSRP3 is perhaps the
best-documented example of a gene encoding a non-sarcomeric protein
that is mutated in hereditary non-syndromic HCM.
Notably, the underlying pathogenic mechanisms of CSRP3 muta-
tions remain unknown. Analysis of myocardium from a patient har-
bouring the CSRP3 p.C58G mutation showed a reduction in MLP level
[4], but the interpretation of this ﬁnding from a single sample of a
patient with advanced disease is potentially confounded by the fact that
MLP expression is highly variable in the myocardium of non-failing
controls and diseased tissue [6, 13, 14].
To address this challenge, we have generated a mouse model car-
rying the C58G mutation (Csrp3 C58G knock-in, KI). This is the ﬁrst
reported knock-in mouse model mirroring the human genetic situation
of a clearly pathogenic (non-syndromic) HCM variant in a non-sarco-
meric protein and, hence, represents a valuable tool in addressing the
disease mechanisms of non-sarcomeric HCM. Comprehensive pheno-
typing of these mice identiﬁed a robust cardiomyopathy phenotype in
the homozygous setting. At the molecular level, unbiased transcriptome
proﬁling combined with analyses of speciﬁc gene and protein candi-
dates provided clear evidence of cardiac remodelling and activation of
hypertrophic signalling pathways, including calcineurin signalling, in
KI homozygotes.
Importantly, we detected a marked reduction in MLP levels. Using a
combination of in vitro and in vivo approaches, we have linked this
protein depletion with increased activity of the ubiquitin-proteasomal
system (UPS). Moreover, our cellular experiments demonstrated that
this protein depletion is a hallmark of multiple HCM-causing MLP
Fig. 1. Cardiac phenotype of KI/+ and KI/KI mice in
comparison to WT mice. A – Characterisation of
cardiac dimensions and function by echocardio-
graphy: Fractional shortening and end-diastolic di-
mensions are shown. For cohort characteristics and a
wider set of echocardiographic parameters please
refer to Table S1. B – Heart weight is increased in KI/
KI mice, values are normalised to tibial length.
****p < 0.0001 versus WT. C – Invasive haemody-
namic assessment of LV performance of the three
genotypes: dP/dtmax, dP/dtmin and relaxation con-
stant Tau are shown at baseline conditions, and
under adrenergic stress (dobutamine infusion at
4 ng g−1 BWmin−1 and 16 ng g−1 BWmin−1).
Where error bars are missing, they are smaller than
the symbols. For cohort characteristics and a wider
set of parameters refer to Table S2.
M. Ehsan et al. Journal of Molecular and Cellular Cardiology 121 (2018) 287–296
288
Fig. 2. Molecular phenotype of KI/+ and KI/KI hearts. A, B – Transcriptome proﬁling by RNAseq: A – KEGG Pathway analysis: The top ﬁve statistically (p < 0.001)
enriched GO terms for KI/KI hearts when compared to WT hearts are shown. B – Heat map shows genes in the KEGG HCM gene set with the strongest up-regulation in
the KI/KI hearts at the top and the genes showing the strongest down-regulation at the bottom. Colours range from dark red to dark blue representing respectively the
highest and lowest expression of a gene. C – Assessment of transcriptional changes by qPCR for genes related to the fetal gene programme (top), hypertrophic
signalling (middle) and ﬁbrosis (bottom). All measurements are normalised to Gapdh; signiﬁcant changes are observed in the hearts of KI/KI mice; *p < 0.05,
***p < 0.001, ****p < 0.0001 versusWT, n= 6 per group. D – Changes in hypertrophic signalling proteins assessed by Western blotting: Fhl1, Carp (Ankrd1) and
Dscr1 (Rcan1) are induced in KI/KI hearts, in line with the activation of hypertrophic signalling pathways. Anti-hypertrophic Fhl2 is down-regulated in these hearts
(for quantiﬁcation see Fig. S5B). Gapdh serves as loading control. The position of marker proteins is indicated (molecular weight in kDa). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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mutations investigated, suggesting that UPS-mediated depletion of MLP
is the unifying underlying driver for the development of non-sarcomeric
HCM caused by mutations in CSRP3.
2. Results
2.1. Generation of Csrp3 C58G knock-in mice
To generate a model system for human HCM caused by a mutation
in CSRP3, the C58G mutation was introduced into exon 3 of the murine
Csrp3 gene by homologous recombination and subsequent removal of
selection markers using FLPe/FRT recombination (Fig. S1A). Mice
carrying the mutation (either heterozygous or homozygous) were vi-
able, fertile and had a normal life span up to the observed 18months of
age. The mutation was detectable at both mRNA (Fig. S2A) and protein
level (Fig. S2B, C). Unless stated otherwise, phenotyping was performed
in young adult male mice (2–3month of age).
2.2. Cardiac phenotype of heterozygous and homozygous Csrp3 C58G KI
mice
Male mice heterozygous or homozygous for the Csrp3 C58G muta-
tion (hereafter referred to as KI/+ and KI/KI, respectively) were
compared to wildtype (WT) controls by transthoracic echocardiography
(Fig. 1A). KI/+ mice had normal cardiac dimensions and function for
all parameters investigated, except for an increase of anterior wall
thickness at the 6month timepoint (Table S1). In contrast, KI/KI mice
had reduced systolic function, enlarged left ventricular (LV) dimensions
and elevated calculated LV mass. In agreement with these in vivo
measurements, heart weight (normalised to tibial length) was increased
for KI/KI mice, but not for KI/+ mice (Fig. 1B).
Invasive LV haemodynamic measurements were performed in all
three genotypes, both at baseline and upon adrenergic stimulation
(dobutamine infusion at two diﬀerent concentrations; Fig. 1C; Table
S2). Once again, KI/+ showed no signiﬁcant diﬀerences to WT mice
under all conditions examined, whereas KI/KI mice had marked dia-
stolic and systolic impairment, as evidenced by increased relaxation
constant Tau and blunted dP/dtmax and dP/dtmin, as well as markedly
reduced contractile reserve in response to beta-adrenergic stimulation
(Fig. 1C, Table S2).
As KI/+ mice did not display an overt phenotype at baseline, we
examined the response of KI/+ mice to mechanical stress induced by
increased LV afterload using transverse aortic constriction (TAC) sur-
gery [15] in an attempt to unmask a subtle phenotype arising due to the
C58G mutation. We observed robust LV hypertrophy at 2 weeks post-
TAC in all banded animals (Fig. S3A). However, the macroscopic and
molecular hypertrophic response to chronic pressure overload did not
diﬀer for KI/+ mice when compared to their WT littermates (Fig. S3,
Table S3).
In summary, KI/+ mice did not display a cardiac phenotype at
baseline or upon challenge by LV pressure overload. In contrast, KI/KI
mice displayed a clear cardiomyopathy phenotype, with impaired sys-
tolic and diastolic function, increased cardiac mass and reduced con-
tractile reserve.
2.3. Transcriptomic proﬁling of Csrp3 C58G KI mice
To gain insights into the molecular changes underlying the cardiac
phenotype observed in the presence of the MLP C58G mutation, we
performed transcriptome proﬁling by RNA-seq on WT and KI/KI mouse
hearts. 622 genes were found to be diﬀerentially expressed (Table S4).
To aid functional interpretation of the diﬀerential transcriptome, we
analysed enriched gene ontology (GO) terms and Kyoto Encyclopedia of
Genes and Genomics (KEGG) pathways. The most enriched KEGG
pathways included extracellular matrix receptor interaction, cell and
focal adhesion, transforming growth factor beta signalling and
glycosaminoglycan biosynthesis, indicating enhanced ﬁbrotic extra-
cellular matrix remodelling in the KI/KI hearts (Fig. 2A). Gene Set
Enrichment Analysis also identiﬁed the HCM-related KEGG pathway as
one of the signiﬁcantly enriched pathways (Fig. 2A): the heat map
(Fig. 2B) highlights the genes within this particular KEGG pathway,
showing the activation of hypertrophic signalling within the diﬀeren-
tially expressed gene set. GOrilla analysis was performed using diﬀer-
entially expressed genes and identiﬁed several enriched GO terms for
these genes. In agreement with alterations in the transcriptome, the
most enriched GO cellular components were “sarcomere” and “extra-
cellular matrix”, while for GO processes “heart rate” and “cellular
proliferation” were found to be most enriched (Fig. S4).
2.4. Molecular characteristics of heterozygous and homozygous Csrp3
C58G KI mice
Based on these results, hearts of mice from all three genotypes were
investigated using more targeted molecular and histological analyses.
In agreement with a macroscopic cardiomyopathy phenotype and the
altered transcriptome proﬁle, qPCR showed striking induction of tran-
scripts related to heart failure and hypertrophic signalling in KI/KI mice
(Fig. 2C), including induction of the fetal gene programme [16].
Moreover, transcripts known to be linked to extracellular matrix re-
modelling and ﬁbrosis were upregulated in these mice (Fig. 2C), while
only one transcript related to apoptosis (Bcl2) was found to be upre-
gulated (Fig. S5A).
Induction of proteins implicated in hypertrophic signalling, such as
Fhl1, Ankrd1/cardiac ankyrin repeat protein (Carp) and calcineurin
responsive Rcan1.4 was conﬁrmed by Western blotting in KI/KI mice
(Fig. 2D), together with a down-regulation of anti-hypertrophic Fhl2
(Fig. 2D, Fig. S5B). In addition, upregulation of β-myosin heavy chain
was conﬁrmed at protein level (Fig. S5C). Histological analysis showed
no diﬀerences between WT and KI/+ mice, with no evidence of ﬁbrosis
(Fig. S6). In contrast, KI/KI mice showed signs of ﬁbrosis, albeit mild,
on Sirius Red staining (Fig. S6), conﬁrming the induction of pro-ﬁbrotic
signalling at transcript level. Taken together, at the molecular level the
hearts of KI/KI mice are characterised by induction of the fetal gene
programme and upregulation of markers of hypertrophy and heart
failure.
2.5. Analysis of MLP expression in Csrp3 C58G KI mice
To assess whether the mutation resulted in any changes to mRNA
and/or protein expression, Csrp3 transcript expression and MLP levels
were measured. Csrp3 transcript was upregulated in KI/KI, but not in
KI/+ mice (Fig. 3A). Surprisingly, however, the abundance of the MLP
decreased in KI/KI mice by 80% and in KI/+ mice by 50% of the WT
level (Fig. 3A, B). This ﬁnding was conﬁrmed by immuno-ﬂuorescence
staining of isolated adult cardiomyocytes. Indeed, the MLP speciﬁc
immunoreactive signal was lower in KI/+ cells than in WT cells, and
this eﬀect was even more pronounced in KI/KI cells (Fig. 3C). Of note,
the localisation of the remaining MLP was diﬀuse with some Z-disc
staining in KI/+ cells, and diﬀuse in KI/KI cells. No nuclear accumu-
lation or aggregation of MLP was observed.
2.6. The Csrp3 C58G KI allele cannot rescue the phenotype in Csrp3/MLP
knock out mice
Inactivation of both alleles of the Csrp3 gene (Csrp3-/-; also known
in the literature as MLP knock out, KO, mice) leads to a striking cardiac
phenotype resembling DCM [7], while hemizygous Csrp3+/- have
normal cardiac dimensions and function at baseline ([17] and Fig. 4
and Fig. S7B, Table S5). To further address the genetic consequences of
the C58G mutation, we generated mice with one Csrp3 null allele and a
Csrp3 C58G allele (designated Csrp3 KI/-). These mice were found to
have a similar level of LV dilatation and reduced fractional shortening
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to Csrp3-/- mice at 2months of age (Fig. 4, Table S6), indicating that
the Csrp3 C58G allele cannot functionally compensate for the loss of the
Csrp3 WT allele on the Csrp3 null background.
2.7. Protein depletion is a common feature of HCM-associated Csrp3
mutations
The observed dramatic reduction of MLP levels in Csrp3 C58G KI
mice suggested that protein depletion could be a common feature of
HCM-associated Csrp3 mutations. To investigate this, C58G and two
additional HCM-causing MLP mutations (L44P and S54R/E55G, [9])
were expressed in mammalian cells in a bicistronic system with a hrGFP
reporter protein. Upon normalisation to hrGFP, all three HCM-asso-
ciated mutations showed reduced protein levels, while transcript levels
were normal, indicating comparable transfection eﬃciency (Fig. 5A,
Fig. S8A). In contrast, a DCM mutation (K69R, [11]), showed similar
protein levels to MLP WT control.
For a more detailed assessment, two HCM mutations (MLP L44P and
Fig. 3. MLP depletion in KI/KI hearts. A –
Measurement of Csrp3 transcript by qPCR (left) and
MLP protein (right) in the three groups, normalised
to Gapdh transcript and protein, respectively. In the
KI/KI mice, Csrp3 transcript is 2.5-fold up-regulated.
The abundance of MLP decreased in KI/KI mice by
80% and in KI/+ mice by 50%. MLP level is down-
regulated to 50% in KI/+ mice and to 20% in KI/KI
mice. ***p < 0.001, ****p < 0.0001 versus WT,
n= 6 per group. B – Representative Western blot
demonstrating reduced MLP levels in KI/+ and KI/
KI mice. Gapdh serves as loading control. The posi-
tion of marker proteins is indicated (molecular
weight in kDa). N.B., both TaqMan probe target site
and epitope of the anti-MLP antibody 79D2 are not
overlapping with the site of the C58G mutation. C –
Immuno-ﬂuorescence on isolated adult cardiomyo-
cytes from mice of the three genotype groups. Cells
are stained for MLP (left), titin M-band epitope m8
(middle) and merged images are shown on the right
(MLP red, titin m8 green). Scale bar represents
20 μm. Insert: Magniﬁed area, scale bar represents
5 μm.
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C58G) were expressed in primary neonatal rat cardiomyocytes (NRC)
using the bicistronic reporter system and adenoviral gene delivery. Both
mutant proteins were expressed at approximately 20% of the level of
WT recombinant protein, with no dominant negative eﬀect on en-
dogenous MLP expression observed (Fig. 5B, C). The protein depletion
was further conﬁrmed using adult Guinea pig cardiomyocytes (Fig.
S8B); WT recombinant protein was detectable as diﬀuse cytoplasmic
protein 48 h post-infection. In contrast, only traces of MLP L44P and
MLP C58G were observed in cells, despite the reporter protein hrGFP
being clearly present in infected cells.
2.8. The UPS is responsible for the protein depletion of HCM-associated
MLP mutants
Two major pathways are known to control protein degradation in
mammalian cells: autophagy and degradation by the UPS (reviewed in
[18]). To test the possible role of these mechanisms in depletion of
mutant MLP, NRCs were transduced with WT or mutant MLP and
treated with inhibitors targeting either autophagy or the UPS. In control
treated cells, both MLP L44P and C58G proteins were destabilised, as
expected (Fig. 6A, Fig. S8C). Inhibition of autophagy with baﬁlomycin
or LY294002 had no eﬀect on mutant MLP depletion in NRC (Fig. S8C
and data not shown), suggesting that autophagy does not mediate
mutant MLP depletion. In contrast, inhibition of the UPS by MG-115 or
MG-132 treatment fully restored mutant MLP to WT levels (Fig. 6A),
indicating that this pathway is indeed responsible for depleting mutant
MLP in these cells.
Using tandem ubiquitin-binding entities (TUBEs, [19]), we pulled
down MLP C58 from lysates of Csrp3 KI/KI hearts (Fig. 6B), suggesting
that MLP C58G is ubiquitinated in vivo. To conﬁrm the role of the UPS
in MLP C58G depletion in vivo, Csrp3 KI/+ and KI/KI mice were in-
terbred with a ubiquitin G76V-GFP reporter line [20]. In this line, the
ubiquitin-GFP reporter protein is constantly turned over, but accumu-
lates upon inhibition [20] or overload [21, 22] of the UPS. While the
ubiquitin-GFP reporter protein was only detectable at low levels in WT
and KI/+ mice, it clearly accumulated in KI/KI mice (Fig. 6C, D),
suggesting overload of the UPS in this mouse model of non-sarcomeric
HCM.
Co-chaperone BCL-2 associated athanogene3 (Bag3) plays im-
portant roles in protein quality control [23] and its crucial role in the
Fig. 4. The Csrp3 C58G allele cannot rescue the phenotype of Csrp3-/- knock out mice. A – Representative examples of M-mode echocardiography of Csrp3+/- mice
with normal systolic function (top), Csrp3 KI/- mice (middle) and Csrp3-/- mice (bottom), the latter both with impaired systolic function. The calculated value of LV
fractional shortening (FS) is given for each mouse. B – Cardiac morphology of the genotypes. Haematoxylin-eosin stained paraﬃn heart sections are shown.
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maintenance of cardiac homeostasis has recently been demonstrated by
cardiomyopathy resulting from loss-of-function mutations in both mice
and humans [24]. Together with its associated proteins, Hsp70 and
Hsc70, Bag3 stabilises small heat shock proteins (Hsps) involved in the
refolding or degradation of unfolded protein substrates. Through co-
immunoprecipitation studies, we found Bag3 to interact with MLP
C58G from Crsp3 KI/KI hearts (Fig. 7A). This prompted us to inter-
rogate the Bag3 chaperone system both at the transcript and protein
level (Fig. 7B, C). We found a striking induction of the Bag3 – Hsp70 –
HSc70 complex in the KI/KI mice, together with an upregulation of
small Hsps, particularly Hsp27.
Taken together, our mouse model provides insights into the pa-
thological mechanisms of cardiomyopathy in the presence of a non-
sarcomeric HCM-causing mutation in CSRP3. Furthermore, our work
indicates that proteasomal degradation by the UPS is responsible for the
depletion of HCM-associated mutant MLP, which is the underlying
driver of the disease.
3. Discussion
Genetic studies have clearly demonstrated that CSRP3 mutations
can cause autosomal dominant HCM [4, 9, 12], even though the en-
coded protein, MLP, is not a sarcomeric protein [4] and hence contra-
dicts the existing paradigm of HCM as a “disease of the sarcomere”.
Consequently, CSRP3 mutations, despite their rarity [12], are me-
chanistically interesting since the mechanisms underlying their patho-
genic eﬀects have not been well understood. To this end, we generated
a mouse model carrying the best characterised CSRP3 mutation – C58G
[4] – (referred to here as Csrp3 KI) to study the pathology underlying
non-sarcomeric HCM.
The newly generated Csrp3 KI mouse model reﬂects aspects of the
human cardiomyopathy, especially in the homozygous setting. The
mice develop cardiomyopathy with diastolic and systolic impairment,
increased LV mass and reduced contractile reserve. At the molecular
level, transcriptome proﬁling shows clear evidence of a pro-ﬁbrotic
signature and alterations in agreement with a HCM-like signature.
RNAseq ﬁndings and qPCR show concordant results with upregulation
of key genes involved in hypertrophy and ﬁbrosis such as Acta1, Myh7,
Tgfb, Nppa, Nppb, Ankrd1/2. GOrilla and KEGG pathway enrichment
ﬁndings were consistent with the phenotype of cardiomyopathy in the
murine model. GO Enrichment score and a strong evidence of sarco-
meric involvement in cellular components, heart rate regulation, and
cell proliferation in biological processes emphasize structural and
functional changes similar to heart failure.
A targeted analysis of transcripts furthermore demonstrated acti-
vation of pro-hypertrophic signalling and re-activation of the fetal gene
programme, both hallmarks of HCM. Additionally, changes indicative
of cardiac hypertrophy and heart failure, e.g. Fhl1 upregualtion and
Fhl2 downregulation [25, 26], Carp induction [27]) and upregulation
of β-myosin heavy chain [28] were observed at the protein level in the
myocardium of KI/KI mice.
Heterozygous KI/+ mice did not develop an overt cardiac pheno-
type even upon aging up to 12months (data not shown). This may be
explained by the fact that HCM caused by CSRP3 mutations is often
characterised by late on-set in humans [4]. Furthermore, there are
various examples that the direct genetic equivalent of a human HCM
mutation does not result in an overt phenotype in mice, as in the case of
myosin binding protein C mutations [22] and myosin heavy chain
mutations [29, 30]. Fundamental diﬀerences in cardiac physiology
between mice and humans, such as the diﬀerent composition of key
protein isoforms (e.g. for myosin heavy chain), substantial diﬀerences
in heart rate and electrical conduction [31, 32], as well as the sedentary
life style of laboratory mice may also contribute to this phenomenon.
Despite not being signiﬁcantly aﬀected, KI/+ mice had a tendency
towards reduced contractile reserve. Moreover, we demonstrated that
the Csrp3 C58G allele did not functionally replace the WT Csrp3 allele,
when the other Csrp3 allele was inactivated.
In order to challenge the KI/+ mice, we employed transaortic
constriction (TAC) surgery. Surprisingly, their hypertrophic response to
aortic banding did not diﬀer to that of their WT littermates, suggesting
that MLP's proposed mechano-sensing function [2] is not required for
the hypertrophic response to TAC. Nevertheless we cannot rule out a
role for MLP in the transition to heart failure, as suggested for a model
of myocardial infarction [17].
Our cellular and molecular analyses of this mouse model
Fig. 5. Protein depletion is a hallmark of HCM-associated MLP mutations. A –
Recombinant HA-tagged MLP WT, HCM-associated MLP mutants (L44P, S44R/
E54G, C58G), a DCM-associated MLP mutant (K69R) and empty parental vector
were expressed in HEK cells, by transfection with a bicistronic vector system
(see Section 1.6 of Material and Methods in Appendix A Supplementary data).
Cell lysates were blotted for MLP (using either anti-HA antibody against the N-
terminal tag, light grey, or anti-MLP antibody 79D2 against the C-terminus of
the protein, dark grey) and hrGFP. In addition, CSRP3 and hrGFP transcripts
were measured by qPCR in parallel transfected cells (black bars). The ratios of
CSRP3 transcript or MLP protein to hrGFP were set to 100% for WT transfec-
tions and all other samples expressed relative to WT, n=3 per group. Note that
all HCM-associated mutants are aﬀected by protein depletion, while the DCM-
associated mutation is not aﬀected. B – NRC were transduced with adenoviral
particles coding for MLP WT, L44P, C58G and empty vector (see A) and cell
lysates were blotted for MLP (using antibody 79D2) and hrGFP. The HA-tag on
the recombinant MLP allows separation of this protein from endogenous rat
MLP by size. Pan-actin serves as a loading control. The position of marker
proteins is indicated (molecular weight in kDa). C – Quantiﬁcation of Western
blots from panel B (grey bars) and measurement of CSRP3 and hrGFP tran-
scripts by qPCR to conﬁrm equal transduction eﬃciency (back bars). Data are
normalised as in panel A. The TaqMan probe is speciﬁc for the recombinant
(human) MLP constructs and does not recognise the endogenous rat Csrp3
transcript.
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Fig. 6. HCM-associated MLP mutant proteins are
subjected to depletion by proteasomal pathways: A –
NRC were transduced with adenoviral particles as in
Fig. 5B and treated with proteasomal inhibitors MG-
115 and MG-132. Cell lysates were blotted for HA,
detecting the recombinant MLP WT, L44P and C58G.
Pan-actin served as loading control and blotting for
ubiquitin conﬁrmed eﬃcient inhibition of the pro-
teasome by accumulation of ubiquitinated proteins.
In control (ctr, DMSO-treated) cells, MLP L44P and
C58G are destabilised, however they are restored to
WT protein levels upon proteasomal inhibition. B –
TUBE assay: Ubiquitinated proteins were pulled
down from Csrp3 KI/KI heart lysate (treated in vivo
with proteasomal inhibitor MG-262 1 μmol/kg BW
for 20 h) using immobilised tandem ubiquitin-
binding entities (TUBE). Agarose matrix without
TUBE served as control (ctr). Lysate controls are
shown (LC, 1% of input). Blotting for ubiquitin (ubi)
indicates the enrichment of ubiquitinated proteins in
the TUBE pulldown. Blotting for MLP shows speciﬁc
pulldown of MLP with TUBE, indicating ubiquitina-
tion of the protein. Please note the higher molecular
weight (> 20 kDa) than normal endogenous MLP
(< 20 kDa, see panel C). C – Proteasomal overload in
the KI/KI mice: The ubiquitin G76 V GFP reporter
(GFP-ub) was crossed onto mice of the three geno-
types. Samples of hearts of 6month old mice were
blotted for GFP and increased accumulation of GFP-
ub was observed in the KI/KI mice, indicating pro-
teasomal overload. Blotting for MLP illustrates the
genotype of the mice and Gapdh served as loading
control. The position of marker proteins is indicated
(molecular weight in kDa). D – Quantiﬁcation of
GFP-ub induction (blots relating to panel C), ex-
pressed relative to Gapdh (left) or MLP (right) pro-
tein levels, n= 6 per group. A striking induction of
the GFP-ub reporter is observed in KI/KI hearts;
**p < 0.01, ***p < 0.001.
Fig. 7. Proteotoxic stress response in the KI/KI mice:
A – Co-immunoprecipitation of MLP and Bag3 from
KI/KI heart lysate (see Fig. 6B). MLP C58G was
precipitated using anti-MLP 79D2 antibody (IP) or
isotype antibody control (ctr). Lysate controls are
shown as detection controls (LC, 1% of input); * in-
dicates signal from antibody chains. Bag3 co-pre-
cipitates with MLP C58G, evidencing a complex
formation between the endogenous proteins. The
position of marker proteins is indicated (molecular
weight in kDa). B – In the KI/KI mice with protea-
somal overload, the protein quality control complex
Bag3 - Hsp70 – Hsc70 is induced and small heat
shock proteins Hsp27, HspB7 and αβ-crystallin
(ABcryst) are upregulated. Please note, the blots for
MLP and loading control Gapdh on the same mem-
brane are already shown in Fig. 3B. The position of
marker proteins is indicated (molecular weight in
kDa). C – Left: Assessment of transcriptional changes
by qPCR for genes related to protein quality control.
All measurements are normalised to Gapdh (n=6
per group); signiﬁcant changes are observed in the
hearts of KI/KI mice for all transcripts apart from
Hsc70 and Hsp70. Right: Quantiﬁcation of protein
levels of proteins involved in protein quality control
(blots of panel 7B). All measurements are normalised
to Gapdh (n= 4 per group); signiﬁcant changes are
observed in the hearts of KI/KI mice for all proteins apart from αβ-crystallin. **p < 0.01, ***p < 0.001, ****p < 0.0001 versus WT.
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demonstrated depletion of mutant MLP in both the heterozygous and
homozygous C58G KI mice. This is in agreement with the ﬁnding of
reduced MLP level in the index patient carrying the CSRP3 C58G mu-
tation [4], and further demonstrated by our cellular experiments, which
consistently conﬁrmed protein depletion as a hallmark of all three
HCM-causing CSRP3 mutations investigated. Moreover, we demon-
strated ubiquitin conjugation of MLP C58G and that the activity of the
UPS is responsible for this protein depletion, while autophagy does not
play a direct role. In this respect, HCM-causing CSRP3 mutations re-
semble mutations in MYBPC3, one of the major sarcomeric disease
genes for HCM: the latter are subject to degradation by the UPS in vitro
[21, 33] and in a mouse model [22]. In the case of both CSRP3 and
MYBPC3 mutations, the overload of the UPS through the constant
turnover of a mutant protein leads to chronic impairment of the system
to fulﬁl its crucial tasks in cellular homeostasis, resulting in accumu-
lation of unfolded proteins. In support of this, we observed the forma-
tion of a protein complex of MLP C58G with Bag3 and induction of the
Bag3 protein quality control system with upregulation of small Hsps,
particularly Hsp27. In the long term, such chronic stressors are thought
to contribute to cardiomyopathy [34] and heart failure [35].
The crucial role for Bag3 in cardiac homeostasis is best understood
for loss of function mutations in the human BAG3 gene [36, 37] and
inactivation of Bag3 in mice [24], both resulting in DCM. However, the
protein has also been implicated in skeletal muscle disease (myoﬁbrillar
myopathy, [38]) and desmin-related cardiomyopathy, e.g. caused by
the R120G mutation in CRYAB [38]. Overexpression of the latter in a
mouse model activates cardiac hypertrophy [39] and Bag3 has been
found to regulate contractility and calcium homeostasis in cardiac cells
[40]. It is plausible that activation of Bag3 protein complex could
contribute to pathogenic activation of hypertrophic signalling cascades
also in the Csrp3 KI/KI mice.
Our recent work has shown that MLP acts as an endogenous in-
hibitor of PKCα activity in non-failing hearts, potentially by providing
an abundant cytoplasmic substrate competing with the activating auto-
phosphorylation of the kinase [6]. In pathological settings such as heart
failure, PKCα is chronically activated and MLP cannot dampen PKCα
activation suﬃciently. Simultaneous induction of Carps leads to a re-
cruitment of a complex of Carps and activated PKCα to the intercalated
disk. It is speculated that chronic PKCα activity in this compartment is
detrimental to the heart, e.g. by aﬀecting adrenergic signalling [41].
In our mouse model, protein depletion through UPS activity results
in a lack of functional MLP and we have further shown that this is a
feature of all three HCM-causing MLP mutations investigated in our
cellular experiments. At the same time, these three HCM mutations
were found to be hypo-phosphorylated by PKCα [6]. However, any
direct eﬀect of the mutant MLP on PKCα activity is irrelevant as the
lack of functional MLP levels through UPS-mediated protein depletion
overrides it. As a consequence, PKCα becomes chronically activated
(Fig. S9) and may cause aberrant induction of heart failure signalling.
As all three HCMmutations are aﬀecting conserved residues in the same
region of the protein, namely the second zinc ﬁnger of the ﬁrst LIM
domain, it is likely that all three aﬀect the protein structure [42] in a
similar way and lead to partial protein unfolding as demonstrated
previously for MLP C58G [4, 43]. These unfolded proteins will be re-
cognised by protein quality control systems (as evidenced by the in-
teraction of MLP C58G with Bag3 and the induction of Bag3 and as-
sociated heat shock proteins in our mouse model) and subsequently be
targeted for degradation by the UPS. The mode of action appears to
diﬀer for DCM-associated mutations: K69R and G72R are located in the
intrinsically unstructured glycine-rich region [42], hence an unfolded
protein response in the presence of the mutations is unlikely. Instead,
these mutations aﬀect MLP's ability to inhibit PKC activity [6]. In ad-
dition, a role of amino acids 64–69 in nuclear shuttling of MLP [8] and
acetylation of K69 [44] are potentially disturbed by both DCM-asso-
ciated mutations.
In conclusion, our newly generated Csrp3 KI mouse model of non-
sarcomeric HCM, combined with extensive cell-based work, provides
important insights into molecular mechanisms underlying pathogenic
eﬀects of HCM-associated CSPR3 mutations.
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